Form 4: ImageneBio CEO Gains Equity, Options in Compensation

ImageneBio CEO Kristin Yarema acquired 85,400 restricted stock units and 128,100 employee stock options on March 16, 2026, as part of her compensation.

Summary

• Kristin Yarema, CEO and Director of ImageneBio, Inc. (IMA), acquired 85,400 shares of common stock through restricted stock units (RSUs) on March 16, 2026.
• Each RSU represents the contingent right to receive one share of Common Stock upon settlement, with an acquisition price of $0.
• The RSUs will vest 25% on March 15, 2027, and the remainder in successive equal quarterly installments over the next 12 Standard Quarterly Dates (March 15, June 15, September 15, December 15), subject to continuous service.
• Additionally, Yarema acquired 128,100 employee stock options on March 16, 2026, with an exercise price of $6.2 per share and an acquisition price of $0 for the option itself.
• These options vest over four years, with 25% vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to continuous service.
• The options have an expiration date of March 16, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a standard and healthy practice of aligning executive incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The equity awards align the Chief Executive Officer's interests directly with those of shareholders, incentivizing long-term company performance.
• The vesting schedules for both RSUs and stock options encourage continuous service and commitment from key management.

Negatives

• The issuance of new equity awards, once vested and exercised, could lead to a degree of share dilution for existing shareholders, though this is standard practice for executive compensation.

Risks

• The value of the acquired RSUs and stock options is subject to the future market performance of ImageneBio's common stock.
• Vesting of both RSUs and options is contingent upon Kristin Yarema's continuous service with the company, as defined in the 2025 Equity Incentive Plan.

Future Outlook

The vesting schedules for the RSUs and stock options extend several years into the future, indicating a long-term commitment from the CEO and a structured approach to executive incentives under the company's 2025 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and employee stock options is a standard and widely adopted practice in executive compensation across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and motivate key leadership by linking their financial success to the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with common practices observed in publicly traded biotechnology companies of similar size and stage.
• The exercise price of $6.2 for the options is typical, often set at the fair market value of the stock on the grant date, aligning with market benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards, but also benefit from increased alignment of CEO's interests with long-term stock performance.
• Employees: The awards are part of the company's 2025 Equity Incentive Plan, which may also benefit other employees, fostering a culture of shared ownership and incentivization.

Next Steps

• The RSUs will begin vesting on March 15, 2027, with subsequent quarterly vesting installments.
• The employee stock options will begin vesting on March 15, 2027, with subsequent monthly vesting installments.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation and does not present new information that would fundamentally alter the investment thesis for ImageneBio. While it aligns management's interests with shareholders, it is a standard event and typically does not warrant a change in investment recommendation.

Keywords

ImageneBio, IMA, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Incentive Plan, CEO Compensation